Ikervis

Ciclosporin, the active ingredient in Ikervis, is a calcineurin inhibitor presented as a 0.1% w/v ophthalmic emulsion for ocular (topical) use. It treats dry eye disease and keratoconjunctivitis sicca by modulating immune‑mediated inflammation on the ocular surface. It is indicated for patients with chronic ocular surface disease.

GNH USA supplies Ikervis as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, providing reliable sourcing, regulatory support and consistent quality for ophthalmic therapeutics and tailored logistics solutions across multiple regions.

Ikervis (ciclosporin) is used to manage ocular surface inflammation associated with dry eye disease and related conditions. - Dry eye disease: reduces ocular surface inflammation and improves tear film stability. - Keratoconjunctivitis sicca: suppresses T‑cell mediated inflammation and alleviates patient discomfort. - Inflammatory ocular surface disease: provides immunosuppressive effect to control chronic inflammation.

Ikervis may cause ocular and systemic adverse reactions, most of which are mild and localized to the eye.

Common Side Effects: - Burning sensation: transient discomfort upon instillation. - Stinging: mild irritation that usually resolves quickly. - Redness: mild conjunctival hyperemia after use.

Serious or Rare Side Effects: - Eye infection: increased risk of bacterial or fungal keratitis. - Corneal ulceration: rare but serious epithelial breakdown. - Elevated intraocular pressure: may require monitoring and treatment.

When prescribing Ikervis, clinicians should observe several precautionary measures to ensure safe use. - Monitor ocular surface: assess inflammation and symptom improvement regularly. - Avoid use in active ocular infection: may exacerbate infection risk. - Assess intraocular pressure: periodic checks recommended during therapy. - Do not combine with other topical immunosuppressants without supervision: risk of excessive immunosuppression. - Store at room temperature: keep in the original container, protect from light and moisture.

Ciclosporin ophthalmic emulsion can interact with systemic and ocular agents; awareness of these interactions helps prevent adverse outcomes.

Major Interactions (Avoid): - Systemic cyclosporine: concurrent use may increase systemic immunosuppression. - Potent CYP3A4 inhibitors (e.g., ketoconazole): may raise systemic exposure if absorbed. - Live ocular vaccines: risk of infection due to immunosuppression.

Moderate Interactions (Monitor Closely): - Topical corticosteroids: additive immunosuppressive effect may increase infection risk. - Anticholinergic eye drops: may affect tear production and drug tolerance. - Contact lens wear: lenses can alter drug distribution and increase irritation.